Commonwealth Equity Services, LLC Macrogenics Inc Transaction History

Commonwealth Equity Services, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$4.82 - $7.24 $1,928 - $2,896	400 Added 3.46%	11,950 $85,000
Q4 2022 Feb 07, 2023	BUY	$3.34 - $6.98 $38,577 - $80,619	11,550 New	11,550 $77,000
Q3 2021 Oct 29, 2021	SELL	$19.74 - $28.7 $148,425 - $215,795	-7,519 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$20.49 - $35.63 $20,490 - $35,630	1,000 Added 15.34%	7,519 $201,000
Q1 2021 May 04, 2021	BUY	$18.99 - $33.2 $123,795 - $216,430	6,519 New	6,519 $207,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.